SELLAS Life Sciences Group Inc. (NASDAQ: SLS) announced that preclinical data on SLS009, its CDK9 inhibitor drug candidate, will be ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE